Group 1 - Danaher Corporation reported fourth-quarter results that exceeded analyst expectations, with adjusted earnings of $2.23 per share and revenue of $6.84 billion, reflecting a year-over-year revenue increase of 4.5% [1] - The company's non-GAAP core revenue increased by 2.5%, driven by strong performance in bioprocessing [1] Group 2 - For the full year 2025, Danaher achieved adjusted earnings of $7.80 per share, marking a 4.5% growth, and revenue of $24.6 billion, which is a 3.0% increase from the previous year [2] - The company generated $6.4 billion in operating cash flow and $5.3 billion in non-GAAP free cash flow [2] Group 3 - Looking ahead, Danaher anticipates low-single-digit core revenue growth in the first quarter of 2026 [3] - For the full year, the company forecasts core revenue growth of 3% to 6% and adjusted earnings between $8.35 and $8.50 per share, with the midpoint slightly above the analyst consensus of $8.42 [3]

Core Insights - Danaher (DHR) shares surged after the company exceeded Wall Street's third-quarter forecasts, driven by strong performance in its bioprocessing division [1][4]. Financial Performance - The biotech division, including bioprocessing, achieved 6.5% organic revenue growth, surpassing the guidance of 6% [2]. - Total sales reached $6.05 billion, a 4% increase, exceeding expectations of nearly $6 billion [3]. - Adjusted earnings per share were $1.89, reflecting a 10.5% growth and beating forecasts of $1.72 [3]. - Diagnostic sales rose by 3.5%, exceeding the high end of projections, while life sciences division sales declined by 1%, missing expectations [3]. Guidance and Market Reaction - Danaher maintained its full-year adjusted earnings guidance of $7.70 to $7.80 per share, slightly below analysts' average estimate of $7.78 [4]. - The company anticipates low single-digit percentage growth in adjusted sales for the year [4]. - Following the earnings report, Danaher stock jumped nearly 8% to $224.37, surpassing the 5% chase zone above a cup base entry of $214.01 [4].